Robert Dwyer Nolan
Directeur/Membre du Conseil chez Phico Therapeutics Ltd.
Postes actifs de Robert Dwyer Nolan
Sociétés | Poste | Début | Fin |
---|---|---|---|
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Robert Dwyer Nolan
Anciens postes connus de Robert Dwyer Nolan
Sociétés | Poste | Début | Fin |
---|---|---|---|
GENEDRIVE PLC | Directeur/Membre du Conseil | 01/01/2004 | 31/12/2018 |
Independent Dir/Board Member | 20/03/2015 | 31/12/2018 | |
Epistem Ltd.
Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - | 01/10/2008 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/1989 | 01/01/2004 |
Cardiff Biologicals Ltd. | Président | - | - |
Fondateur | - | - | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | 15/11/2010 | - |
Cardiff Protides Ltd. | Président | - | - |
NeuTec Pharma Ltd.
NeuTec Pharma Ltd. BiotechnologyHealth Technology NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom. | Directeur/Membre du Conseil | 01/10/2003 | - |
Formation de Robert Dwyer Nolan
King's College London | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 10 |
Opérationnelle
Director/Board Member | 5 |
Chairman | 2 |
Independent Dir/Board Member | 1 |
Sectorielle
Health Technology | 6 |
Commercial Services | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
GENEDRIVE PLC | Health Technology |
ASTRAZENECA PLC | Health Technology |
Entreprise privées | 6 |
---|---|
NeuTec Pharma Ltd.
NeuTec Pharma Ltd. BiotechnologyHealth Technology NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom. | Health Technology |
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Cardiff Protides Ltd. | Commercial Services |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Cardiff Biologicals Ltd. | Commercial Services |
Epistem Ltd.
Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Robert Dwyer Nolan
- Expérience